keyword
MENU ▼
Read by QxMD icon Read
search

Peritoneal dialysis cinacalcet

keyword
https://www.readbyqxmd.com/read/27698566/calciphylaxis-in-peritoneal-dialysis-patients-a-single-center-cohort-study
#1
Yanchen Zhang, Kristin M Corapi, Maria Luongo, Ravi Thadhani, Sagar U Nigwekar
BACKGROUND: Calciphylaxis is a rare but devastating condition in end-stage renal disease (ESRD) patients. Most research in the field of calciphylaxis is focused on hemodialysis (HD) patients; however, data on calciphylaxis incidence, risk factors, and mortality in peritoneal dialysis (PD) patients are limited. METHODS: In this cohort study, we examined data from adult patients who initiated PD for ESRD management at our institute's PD unit from January 2001 to December 2015...
2016: International Journal of Nephrology and Renovascular Disease
https://www.readbyqxmd.com/read/26702005/chronic-kidney-disease-mineral-bone-disorder-in-the-elderly-peritoneal-dialysis-patient
#2
REVIEW
James Goya Heaf
PURPOSE: The purpose of this paper was to review the literature concerning the treatment of chronic kidney disease-mineral bone disorder (CKD-MBD) in the elderly peritoneal dialysis (PD) patient. RESULTS: Chronic kidney disease-mineral bone disorder is a major problem in the elderly PD patient, with its associated increased fracture risk, vascular calcification, and accelerated mortality fracture risk. Peritoneal dialysis, however, bears a lower risk than hemodialysis (HD)...
November 2015: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
https://www.readbyqxmd.com/read/26252263/-the-use-of-cinacalcet-in-chronic-kidney-disease-a-case-report
#3
Roberta Russo, Gennaro Argentino, Immacolata Daniela Maresca, Giuseppina Sannino, Andrea Memoli, Bruno Memoli
Secondary Hyperparathyroidism is an important concurrent cause of cardiovascular and osteo-articular events, as well as, high morbidity and mortality for patients suffering from chronic kidney disease in conservative therapy and dialysis. The usual therapies, such as the vitamin D active metabolites and the phosphate binders did not always demonstrate effective in SHP control. New drugs, such as the calcimimetics, are available, resulting beneficial in highly reducing PTH levels. The only calcimimetic drug clinically used is cinacalcet, whose use is planned only in patients undergoing dialysis (peritoneal and extracorporeal)...
July 2015: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/25709494/calciphylaxis-in-end-stage-renal-disease-prior-to-dialytic-treatment-a-case-report-and-literature-review
#4
Ramón Alberto Tamayo-Isla, Mauro Cuba de la Cruz
INTRODUCTION: Calciphylaxis is a rare medical condition that is usually diagnosed in patients suffering from end-stage renal disease who are already receiving renal replacement therapy and in those post-transplantation. The pathogenesis still remains to be fully elucidated; hence, the treatment is not uniform. The prognosis is generally poor. The ulcerative stage exhibits a worse prognosis than the nonulcerative one. Calciphylaxis presenting in terminal kidney disease prior to dialytic treatment has only rarely been reported...
2015: International Journal of Nephrology and Renovascular Disease
https://www.readbyqxmd.com/read/25590845/cinacalcet-in-pediatric-and-adolescent-chronic-kidney-disease-a-single-center-experience
#5
Abdulla A Alharthi, Naglaa M Kamal, Mohamed W Abukhatwah, Laila M Sherief
Cinacalcet, a calcimimetic drug, has been shown to be efficacious in adult chronic kidney disease (CKD) patients; however, it was not fully studied in pediatric CKD patients. We aimed at assessing the effect of cinacalcet on intact parathyroid hormone (iPTH) secretion in children with CKD-4/5 with iPTH consistently ≥ 300 pg/mL refractory to conventional treatment. This is a prospective cohort analysis of 28 children with uncontrolled hyper-parathyroidism secondary to stage 4 and 5 CKD admitted to a tertiary center during the period from April 2012 to April 2014...
January 2015: Medicine (Baltimore)
https://www.readbyqxmd.com/read/25309151/cinacalcet-administration-by-gastrostomy-tube-in-a-child-receiving-peritoneal-dialysis
#6
Kristen R Nichols, Chad A Knoderer, Bethanne Johnston, Amy C Wilson
A 2-year-old male with chronic kidney disease with secondary hyperparathyroidism developed hypercalcemia while receiving calcitriol, without achieving a serum parathyroid hormone concentration within the goal range. Cinacalcet 15 mg (1.2 mg/kg), crushed and administered via gastrostomy tube, was added to the patient's therapy. This therapy was effective in achieving targeted laboratory parameters in our patient despite instructions in the prescribing information that cinacalcet should always be taken whole.
July 2014: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://www.readbyqxmd.com/read/25123022/targets-for-parathyroid-hormone-in-secondary-hyperparathyroidism-is-a-one-size-fits-all-approach-appropriate-a-prospective-incident-cohort-study
#7
MULTICENTER STUDY
Emmanuelle Laurain, Carole Ayav, Marie-Line Erpelding, Michèle Kessler, Serge Briançon, Laurent Brunaud, Luc Frimat
BACKGROUND: Recommendations for secondary hyperparathyroidism (SHPT) consider that a "one-size-fits-all" target enables efficacy of care. In routine clinical practice, SHPT continues to pose diagnosis and treatment challenges. One hypothesis that could explain these difficulties is that dialysis population with SHPT is not homogeneous. METHODS: EPHEYL is a prospective, multicenter, pharmacoepidemiological study including chronic dialysis patients (≥ 3 months) with newly SHPT diagnosis, i...
2014: BMC Nephrology
https://www.readbyqxmd.com/read/25035446/successful-treatment-of-calciphylaxis-by-a-multidisciplinary-approach
#8
Lisa Borges, Pedro Rosa, Emanuel Dias, Isabel Cássio
A 48-year-old woman performing peritoneal dialysis for end-stage renal disease presented with a painful leg ulcer. The investigation revealed an elevated parathyroid hormone level and the histological examination of the biopsy tissue from the ulcer revealed medial calcification of the arterioles, consistent with calciphylaxis. The patient developed additional ulcers in the lower limbs and treatment with antibiotics, cinacalcet, sevelamer, sodium thiosulfate, low calcium dialysate and hyperbaric oxygen therapy was instituted...
2014: BMJ Case Reports
https://www.readbyqxmd.com/read/24589316/effect-of-cinacalcet-treatment-on-vascular-arterial-stiffness-among-peritoneal-dialysis-patients-with-secondary-hyperparathyroidism
#9
Kai Ming Chow, Cheuk Chun Szeto, Bonnie Ching-Ha Kwan, Phyllis Mei-Shan Cheng, Wing Fai Pang, Chi Bon Leung, Philip Kam-Tao Li
AIM: Although calcimimetics cinacalcet can reduce parathyroid hormone level and control secondary hyperparathyroidism in end-stage renal disease patients, risk of vascular calcification remains high. Whether cinacalcet can further reduce vascular damage or arterial stiffness is unknown. METHODS: We studied the effect of cinacalcet in 33 peritoneal dialysis patients with inadequately controlled secondary hyperparathyroidism despite standard treatment. The primary outcome was the aortic pulse wave velocity at 26 and 52 months after cinacalcet treatment...
June 2014: Nephrology
https://www.readbyqxmd.com/read/24308109/calciphylaxis-a-devastating-complication-of-derangements-of-calcium-phosphorus-metabolism-a-case-report-and-review-of-the-literature
#10
REVIEW
Trish Carter, Shobha Ratnam
Calciphylaxis is a rare and potentially devastating condition also referred to as uremic gangrene syndrome, calcific uremic arteriolopathy, metastatic calcification, and uremic small-vessel disease that can present in patients with end stage renal disease. This article reports a case of a 38-year-old African-American female on peritoneal dialysis for six years with a known history of non-adherence with diet, medications, and prescribed peritoneal dialysis treatment regimen. At her monthly clinic visit, the patient complained of burning sensation in the fingers of both hands with limited fine motor movement due to edema and severe pain...
September 2013: Nephrology Nursing Journal: Journal of the American Nephrology Nurses' Association
https://www.readbyqxmd.com/read/23705925/cinacalcet-lowering-of-serum-fibroblast-growth-factor-23-concentration-may-be-independent-from-serum-ca-p-pth-and-dose-of-active-vitamin-d-in-peritoneal-dialysis-patients-a-randomized-controlled-study
#11
RANDOMIZED CONTROLLED TRIAL
Hyo Jin Kim, Hyunsuk Kim, Nara Shin, Ki Young Na, Yong Lim Kim, Daejung Kim, Jae Hyun Chang, Young Rim Song, Young-Hwan Hwang, Yon Su Kim, Curie Ahn, Joongyub Lee, Kook-Hwan Oh
BACKGROUND: Elevated serum level of fibroblast growth factor-23 (FGF23) is associated with adverse outcomes in dialyzed patients. OBJECTIVES: The CUPID study compared the efficacy of a cinacalcet-based regimen with conventional care (vitamin D and P binders) for achieving the stringent NKF-K/DOQI targets for peritoneal dialysis (PD) patients. Additionally, we analyzed change in FGF23 levels between two treatments to explore the cinacalcet effect in lowering FGF23...
2013: BMC Nephrology
https://www.readbyqxmd.com/read/23382299/short-and-middle-term-continuous-use-of-cinacalcet-in-children-on-peritoneal-dialysis
#12
John Dotis, Nikoleta Printza, Chrisa Ghogha, Fotios Papachristou
BACKGROUND: Secondary hyperparathyroidism (HPT) constitute a high-turnover bone disease, manifested by elevated parathyroid hormone. Cinacalcet, belonging to calcimimetics, has been shown to be promising in the control of secondary HPT with limited data in children. OBJECTIVE: To evaluate the safety and efficacy of cinacalcet in children on peritoneal dialysis (PD) with secondary HPT. METHODS: Four patients on PD with severe secondary HPT, uncontrolled with phosphorus dietary restrictions combined with phosphate binders and analog of 1,25 vitamin D3 received cinacalcet...
2013: Journal of Pediatric Endocrinology & Metabolism: JPEM
https://www.readbyqxmd.com/read/23364628/paricalcitol-reduces-proteinuria-but-does-not-modify-peritoneal-protein-loss-in-patients-on-peritoneal-dialysis
#13
J Emilio Sánchez-Álvarez, Carmen Rodríguez-Suárez, Diego Coronel-Aguilar, Isabel González-Díaz, Miguel Núñez-Moral, Beatriz Peláez-Requejo, Ana Fernández-Viña, Aurora Quintana-Fernández
INTRODUCTION: Paricalcitol, a selective activator of Vitamin D receptors, is successfully used as a treatment of hyperparathyroidism secondary to chronic kidney disease (CKD). In addition, it has been proposed for reducing proteinuria in patients with CKD. Nonetheless, little is known about its effect on peritoneal protein loss in patients on peritoneal dialysis (PD). OBJECTIVES: To analyse the efficiency of oral paricalcitol in secondary hyperparathyroidism control in PD patients and to verify its effect on urinary and peritoneal effluent protein loss...
January 18, 2013: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
https://www.readbyqxmd.com/read/23332991/early-trends-from-the-study-to-evaluate-the-prospective-payment-system-impact-on-small-dialysis-organizations-stepps
#14
MULTICENTER STUDY
Steven M Brunelli, Keri L Monda, John M Burkart, Matthew Gitlin, Peter J Neumann, Grace S Park, Margarita Symonian-Silver, Susan Yue, Brian D Bradbury, Robert J Rubin
BACKGROUND: Launched in January 2011, the prospective payment system (PPS) for the US Medicare End-Stage Renal Disease Program bundled payment for services previously reimbursed independently. Small dialysis organizations may be particularly susceptible to the financial implications of the PPS. The ongoing Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS) was designed to describe trends in care and outcomes over the period of PPS implementation...
June 2013: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/23078546/the-clinical-utility-of-serum-tartrate-resistant-acid-phosphatase-5b-in-the-assessment-of-bone-resorption-in-patients-on-peritoneal-dialysis
#15
Shunsuke Yamada, Kazuhiko Tsuruya, Hisako Yoshida, Masatomo Taniguchi, Naoki Haruyama, Shigeru Tanaka, Masahiro Eriguchi, Toshiaki Nakano, Takanari Kitazono
OBJECTIVES: Serum tartrate-resistant acid phosphatase 5b (TRACP5b) is a bone resorption marker used in the assessment of bone metabolic status. The present study was designed to determine the clinical characteristics and utility of measuring serum TRACP5b levels in peritoneal dialysis (PD) patients. DESIGN: Cross-sectional study. PATIENTS: Forty-one patients receiving PD treatment in a single centre. MEASUREMENT: Serum levels of the bone turnover markers TRACP5b, N-terminal cross-linking telopeptide of type 1 collagen (NTX), bone-specific alkaline phosphatase (BAP), and parathyroid hormone (PTH) were simultaneously measured...
June 2013: Clinical Endocrinology
https://www.readbyqxmd.com/read/22669774/the-efficacy-of-cinacalcet-combined-with-conventional-therapy-on-bone-and-mineral-metabolism-in-dialysis-patients-with-secondary-hyperparathyroidism-a-meta-analysis
#16
Dan Li, Leping Shao, Haiyan Zhou, Wei Jiang, Wei Zhang, Yan Xu
Cinacalcet, the first calcimimetic to be approved for the treatment of secondary hyperparathyroidism (SHPT) in the chronic kidney disease patients, offers a novel therapeutic approach to SHPT. The aim of this meta-analysis is to access the efficacy and safety of cinacalcet on bone and mineral metabolism disorders in the dialysis patients with SHPT. Randomized controlled trials on cinacalcet combined with vitamin D and/or phosphate binders in the dialysis patients with SHPT were identified in Pubmed, Sciencedirect, and the Cochrane library...
February 2013: Endocrine
https://www.readbyqxmd.com/read/22652729/calcimimetics-in-peritoneal-dialysis-patients
#17
REVIEW
Piergiorgio Messa, Claudia Castelnovo, Antonio Scalamogna
Though the prevalence of secondary hyperparathyroidism (SHP) and the related mineral metabolism (MM) changes have been reported at almost the same rate in peritoneal dialysis (PD) as in hemodialysis (HD) patients, PD patients have a higher prevalence of adynamic bone disease (ABD), suggesting that their bone is less sensitive for a given level of PTH. Furthermore, the phosphorus control seems to be better and vitamin D deficiency is more common in PD patients than in HD patients. So, the therapeutic approach to SHP and MM changes in PD patients might be different from the one applied to HD patients...
2012: Contributions to Nephrology
https://www.readbyqxmd.com/read/22383721/cinacalcet-improves-control-of-secondary-hyperparathyroidism-in-peritoneal-dialysis-a-multicenter-study
#18
MULTICENTER STUDY
José Portolés, Paula López-Sánchez, María Auxiliadora Bajo, Inés Castellano, Gloria del Peso, José Ramón Rodríguez, Mayte Ribera, Almudena Ortigosa, Rafael Selgas
No abstract text is available yet for this article.
March 2012: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
https://www.readbyqxmd.com/read/22073845/does-cinacalcet-hcl-an-oral-calcimimetic-agent-for-the-treatment-of-secondary-hyperparathyroidism-improve-arterial-stiffness-in-patients-on-continuous-ambulatory-peritoneal-dialysis
#19
Hiromichi Suzuki, Tsutomu Inoue, Yusuke Watanabe, Tomohiro Kikuta, Takahiko Sato, Masahiro Tsuda, Kousuke Uchida
Vascular calcification (VC) and arterial stiffness (AS) are major contributors to cardiovascular disease, and in chronic kidney disease, VC and AS are correlated. Disorders of calcium and phosphate metabolism contribute to the progression of VC and to increases in AS. The efficacy of cinacalcet (CIN) in reducing AS in patients on continuous ambulatory peritoneal dialysis (CAPD) has not been determined. The present study enrolled 19 CAPD patients (12 women, 7 men; mean age: 62.2 +/- 3.6 years) with serum intact parathyroid hormone (iPTH) greater than 500 ng/dL (mean value: 675 +/- 106 ng/dL) in whom daily oral treatment with CIN 25 mg was started...
2011: Advances in Peritoneal Dialysis
https://www.readbyqxmd.com/read/21762640/improved-parathyroid-hormone-control-by-cinacalcet-is-associated-with-reduction-in-darbepoetin-requirement-in-patients-with-end-stage-renal-disease
#20
M Battistella, R M A Richardson, J M Bargman, C T Chan
BACKGROUND: Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to erythropoietin (EPO) resistance. Medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on darbepoetin dosing is unknown. METHODS AND AIMS: We conducted a retrospective cohort study of 40 end-stage renal disease (ESRD) patients (age: 55 ± 14; mean ± SD; 21:male) who had at least 12 months of cinacalcet therapy. The distribution of renal replacement therapies were: 14 peritoneal dialysis, 18 conventional hemodialysis and 8 nocturnal hemodialysis...
August 2011: Clinical Nephrology
keyword
keyword
84122
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"